Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy - Johnson & Johnson (NYSE:JNJ)

Benzinga

Center

High Factuality

Johnson & Johnson's TARIS Platform - Goldman Sachs Outlines Potential For The Bladder Cancer Therapy - Johnson & Johnson (NYSE:JNJ)

Over the weekend, Johnson & Johnson (NYSE:JNJ) shared data from its TARIS platform assets (TAR-210 and TAR-200) in patients with different types of bladder cancer. Goldman Sachs notes that the company has framed the platform as having a peak revenue potential of over $5 billion. The analyst states that Johnson & Johnson emphasized the ease of administering their TARIS platform device-based therapy from a clinical management perspective.  The pro…